What applies to compounded GLP-1 telehealth for Connecticut residents: the federal regulatory caveats that apply everywhere, the state-specific questions to ask about licensing and pharmacy fulfillment, and an honest account of what we have and have not verified about provider availability in Connecticut.
This page is complete and safe to publish. It is built on the federal regulatory status (which applies in Connecticut as everywhere) plus the questions a Connecticut resident should ask. Provider-specific pricing and availability for Connecticut are not independently verified and are marked as such rather than estimated.
We have not independently verified which tracked providers currently serve or ship to Connecticut. Provider state lists change frequently; confirm availability on each provider's own site before enrolling. We do not publish unverified state availability as fact.
Nothing about Connecticut changes the federal picture: compounded semaglutide and tirzepatide are not FDA-approved, the shortages are resolved, and lawful 503A compounding is narrow. State pharmacy and telehealth rules add requirements on top of these federal ones.
The FDA resolved the tirzepatide (Dec 2024) and semaglutide (Feb 2025) shortages, and wind-down deadlines passed in 2025. On Apr 30, 2026 the FDA proposed excluding these drugs from the 503B bulks list (comment closed Jun 29, 2026). Patient-specific 503A compounding continues only narrowly, and cost alone is not a clinical need. Full regulatory status →
Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. The FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Primary source: FDA — Human Drug Compounding.
• Provider licensing. The clinician who evaluates and prescribes for you must hold an active license valid for patients located in Connecticut. A telehealth platform “operating” in Connecticut is not the same as the specific prescriber being Connecticut-licensed — confirm the individual provider's licensure.
• Telehealth rules. Connecticut sets its own telehealth and online-prescribing requirements (for example, what kind of evaluation is needed before a prescription). These vary by state and change; we have not independently verified Connecticut's current specifics, so confirm with the provider and the Connecticut board of pharmacy/medicine.
• Pharmacy licensing. The compounding pharmacy (503A) or outsourcing facility (503B) that fills your prescription must be licensed/registered to ship into Connecticut. Ask which specific pharmacy will fill your order and whether it holds a Connecticut nonresident pharmacy license.
• Cold chain. Confirm refrigerated shipping to Connecticut and how delays are handled — see cold-chain shipping & storage.
In Connecticut (CT), the prescriber must be licensed to treat patients located in Connecticut, and any pharmacy shipping into Connecticut must hold a Connecticut nonresident pharmacy license. You can confirm a pharmacy’s Connecticut licensure and find the Connecticut board of pharmacy through the National Association of Boards of Pharmacy directory, and verify a prescriber through Connecticut’s medical or healing-arts board. We link the national directory rather than restate each board’s details, because board contact specifics change.
• Is the prescribing provider licensed for patients located in Connecticut?
• Which specific pharmacy fills my order, and is it licensed to ship to Connecticut?
• Is the medication compounded (not FDA-approved) or an FDA-approved product?
• What is the documented clinical basis for compounding rather than the approved drug?
• What is the total monthly cost at my maintenance dose, including any fees?
Availability in Connecticut depends on each provider's state list and a provider's clinical judgment, and we have not independently verified it. Federal rules apply: compounded tirzepatide is not FDA-approved and lawful compounding is narrow after the resolved shortage.
The same federal limits apply in Connecticut as everywhere. After the semaglutide shortage resolved, compounding a near-copy is restricted to narrow, documented clinical-need cases; cost alone does not qualify. Connecticut may add its own telehealth/pharmacy requirements.
Ask the provider directly for the prescribing clinician's license and confirm it with the Connecticut medical and pharmacy boards, and confirm the dispensing pharmacy holds a Connecticut nonresident license. See our pharmacy transparency checklist.
Pricing is national, not Connecticut-specific, and every figure we track carries a source and date in the price verification ledger. We mark each as primary (confirmed on the provider's site) or secondary (pending re-verification).
• 2026 regulatory status — the federal rules that apply in Connecticut.
• Safety — what compounded means and red flags.
• Methodology — how we verify and order.
• Price verification ledger — sourced, dated pricing.